Q3 2023 Inotiv Inc Earnings Call
Welcome to the conference call discontinued discipline by your conference will begin shortly.
[music].
Good afternoon, ladies and gentlemen, and welcome to the third.
Third quarter 2020 earnings conference call at this time all lines are in a listen only mode. Following the presentation. We will conduct a question and answer session. If at any time during this call to require immediate assistance. Please press star zero for the operator this call is being recorded on Thursday.
In 2023, I would now like to turn the control over to Mr. Bob <unk>. Thank you. Please go ahead.
Thank you operator, and thank you everyone for joining today's call with NHS management team.
Before we begin I'd like to remind everyone that some of the statements that management will make on this call are considered forward looking statements.
<unk> statements about the company's future operating and financial results and plants such statements are subject to risks and uncertainties that could cause actual performance or achievements to be materially different from those projected.
Such statements represent management's expectations as of today's date.
You should not place undue reliance on these forward looking statements and the company does not undertake any obligation to update or revise forward looking statements, whether as a result of new information future events or otherwise.
Please refer to the company's SEC filings for further guidance on this matter.
We will also discuss certain non-GAAP financial measures in an effort to provide.
All information for investors.
The condition of these non-GAAP measures and reconciliation to the most comparable GAAP measures are included in the company's earnings release, which has been posted to the investors section of the company's website www.
In it to co dot com.
Also available in the form 10, excuse me 8-K filed with Securities and Exchange Commission.
If you Havent obtained a copy of today's press release, you may do so by going to the investors section of initiatives website.
Joining us from the company. This afternoon are Bob Leisure, President and Chief Executive Officer, Beth Taylor, Chief Financial Officer, and John <unk>, The Companys Chief strategy Officer.
Bob will begin with some opening remarks, after which Beth present, a summary of the Companys financial results and then we will open the call for questions from our analyst. It's my pleasure turn the call over to Bob Leisure CEO Bob. Please go ahead.
Thank you Bob and good afternoon, everyone.
Before we dive into the quarter's results I want to start the call by framing some of our efforts to date, how far we've come in the last few years and how we position ourselves to continue to execute on our plans and goals.
Our investments and growth have been guided by seven strategically planned key objectives first rightsize the infrastructure. After several acquisitions. We are currently in the final stages of optimizer infrastructure right sizing the company's global footprint in order to improve client service and program management.
Well it is competitively positioned our company as a mid sized full service CRO in research model provider.
We feel that completing this objective will allow us to compete even more effectively with smaller as well as larger CRO in research model providers.
Second we reduced the dependency on third party providers.
And focus on becoming a full service provider in order to meet our clients' needs, we developed internal capabilities, both organically and through acquisitions and in doing so we have been able to reduce our reliance on third parties for external services. This in turn reduces costs, but also enhances speed quality overall value for our customers we expect.
This will support continued gross margin improvements.
Third strategic capital investments capital investments have included updating our global technology, which was appropriate and necessary to have significantly larger organization.
We've also updated our enterprise resource planning and customer relationship management assistance as well as our enterprise solution and laboratory systems for managing preclinical studies and our labs.
Additionally, we are committed to addressing deferred maintenance and acquired sites and expanding acquired facilities to allow for growth and leveraging our fixed cost structure.
Fourth rebranding.
Rebranded our services business.
And we're driven by philosophy that customers should expect more from the CRO and to further the awareness.
Now I'll provide a more complete spectrum of services.
Fifth animal welfare passionate regarding our continued commitment to and standards for animal welfare welfare.
This has included focusing increased monies and attention to retain experienced securing staff recruiting and retaining talented passionate leadership, providing appropriate training implementing our site optimization plan, making investments in facilities when required.
Sixth workplace satisfaction.
Diligently to foster positive entrepreneurial work environment around our shared purpose of helping clients bring life saving therapies to people around the world.
This shared purpose combined with fair compensation.
We're a long way to recruiting and retaining top talent to this and we are very proud to have been selected as the recipient.
And our gauges top workplaces USA award earlier, this year and have seen significant improvement our ability to recruit and retain people.
So supply chain synergies, we've been working with our supply chain and vendors to generate synergies from increased volumes from acquisitions and a broader range of services. This has led to additional vendors and alternative supply opportunities, which enables cost reductions from greater purchasing power that we continue to realize.
I also think it's important to reiterate reiterate briefly how the company has evolved over the past six years and our focus on these key objectives outlined today, our preparedness for the next chapter of our story.
Early 2018 with two locations at a 120 people. The company was firmly focused on preclinical safety assessment segment of the drug development market. In 2018, 2019, we completed several acquisitions and began to develop new services organically that organization became inactive in 2019.
Were targeting small and midsized biopharma companies that are clients fleet were being underserved by larger cro's.
Over the next four years somebody as these organically grown service offerings.
<unk>.
Safety Pharmacology juvenile toxicology said reporting clinical pathology biotherapeutics genetic toxicology expanding our range of services has now enabled us to reduce our reliance on third party suppliers to meet our clients' needs enhance margins and.
And improve the overall value provided to our customers and.
In 2021, we began to further expand our offering to the acquisitions, which not only enhanced and it is preclinical services, but also provided a strong foundation to build our discovery based platform.
In fiscal year.
Year 2022, we secured access to key research models to support and complement our DSA services became a major supplier of both small and large research models and diets to the acquisition of Veeco and subsequent subsequently two other critical research model providers.
Acquiring these businesses enhanced our ability to access critical research models and addressed a major risk we identified it and supply chain.
These acquisitions provided our customers with the additional confidence in our ability to meet their needs, which is even more important the.
Access to an HP is limited.
Since the expansion into research model business, we prioritized improvements in animal care and welfare by enlarging our veterinary team consolidating facilities, which allowed us to make significant infrastructure improvements and the remaining facilities. Ultimately we believe these efforts will allow us to increase our margins remain.
With regards to new business development, while continuing our key strategic objectives of enhancing animal welfare.
Today through these acquisitions and the eight organically develop service offerings.
We now currently operate 24 sites across the U S and Europe , serving over 3000 customers employing over 200 professionals worldwide, including industry recognized experts across a wide range of scientific disciplines.
We have evolved to a CRO with the ability to serve clients who require a full breadth of products and services under one group, while delivering those services with a personal touch and being highly responsive the scientific credibility, we still have room for improvement but.
But we are but we get better every month and we believe we will be much better in the future.
If you haven't done. So recently encourage you review the solution stage opportunistic website, there you'll find a comprehensive suite of discovery preclinical and clinical safety assessment services and an extensive offering.
Standard and custom research models support services diets embedding for research and development at.
At present <unk> has become an organization that enables clients to advanced programs from concept to clinic by strategic filling the gaps with our spectrum of services and products.
Now our story shifting to <unk> next chapter in our strategy will continue to evolve in 2023 and further take shape in 2024, as we plan to further improve our service levels profitability and continue our growth.
With this in mind, let's get to the financial results.
Year to date 2023 revenues for $431 7 million up 9% versus the same period last year.
Our revenue for the last nine months, where discovery and safety assessment and research model services grew 11% at 8%, respectively as compared to the same period a year ago.
The third quarter of 2023 was the strongest performing quarter of the fiscal year.
With revenues of $157 5 million.
For Q3, 2023 versus Q3, 2022 revenues were down 9% year over year. However, it was our first quarter profitability.
DSA revenue decreased 5% year over year in Q3, primarily driven by our discovery services, which we believe is a result of decline in the overall biotech funding and the market plus the timing of some general toxicology.
Services somewhat offset by increased revenues from general from the genetic toxicology services in connection with the new business at our Rockville facility.
RMS revenue for the quarter was down 10%, mainly due to significant reduce volume with HP.
In a small and small animal sales somewhat offset by increased pricing.
Integration plans remain on target for this quarter.
This has been important to increase effectiveness and reduce our cost.
We have previously announced mine site closures and completed as planned by the end of.
This June .
The Knights previously announced plant closure is black to our facility in the UK is consol.
Consolidation into Hillcrest is expected to be finalized by the end of Q3 of next year.
In addition, we are closing a small facility in Spain, which is now substantially complete.
We will relocate our facility in Everett, Washington to our expanded operations in Fort Collins, Colorado.
<unk>, which we expect to complete in fiscal Q1 2024.
Over the last 12 months, we have largely now completed nine of the 11 closures mainly by consolidating the operations of these closed facilities into existing operations.
Moreover, most of the planned expansions are now also completed.
Final expansion in Fort Collins remains on track to be completed by the end of the fourth quarter of this fiscal year.
Or do you have for book to Bill This increased capacity expect revenue to begin in Q1 fiscal 2024.
We are now focused.
On the sale of assets from sites, which were closed including Boyertown Cumberland.
Along with ours really businesses, which are under contract.
Negotiations are ongoing regarding the sale of other locations and Hastings, Michigan, Spain.
And Blackstone in UK.
We believe these asset sales may potentially be completed over the next two to three quarters.
Our integration efforts and site closures also given us the opportunity to restructure our transportation system for research models business, which is currently in process. In addition to improved margins related to consolidating our operations. We also believe the sale of the sites planned for closure, we will generate additional cash for the company.
From the perspective of future growth, we will focus on optimizing operations with our new facility footprint, realizing the benefits from the investments recently made.
Many of our sites.
Which will also allow us to bring more service capabilities online.
Overall, we expect to grow our DSA business from $160 million in 2022 to an estimated $180 million in 2000 through 2023.
<unk> in excess of $200 million 2024.
We ultimately is DSA expansion projects.
Recently completed will allow us to grow our DSA sales by 40% to 50% above the 2022 DSA sales levels allow us to leverage our DSA fixed cost structure and infrastructure.
We also anticipate we have capacity to grow the RMS business and expect to reduce our RMS expenses by approximately $20 million. After all these restructuring changes are implemented.
We believe the lack of NXP imports from Cambodia continues to affect the industry's entire supply of research models being imported to the U S.
According to the USDA global agricultural trade system, 2023 imports and hps to the U S year to date through June now 47, 9% lower than those of the same period 2022.
We have begun to identify additional suppliers and increased our imports of hps from countries outside of Cambodia.
Pricing of Hps and related costs continue to increase we continue to generate positive margins, we've been meeting our customers' requirements.
Our safety assessment service offerings have not been impacted by the industry shortage.
However, the suppliers identified in countries other than Cambodia in China.
HP volume available from them are not sufficient to make up for the volume advantage fee exports from Cambodia in prior years.
We sold fewer hps in Q3 than we did in Q2.
Q2 was less than Q1.
We expect to have fewer hp's available for sale in Q4, and we actually sold in Q3.
We will sell less and hps in fiscal 2023.
Fiscal 2022, and if the situation in Cambodia in China stay the same we expect we will have fewer hp's available for sale in fiscal 2024 versus fiscal 2023.
Due to increases in pricing or sales dollars have remained fairly consistent this year, despite the reduced volumes.
If we're able to implement continued price increases we could see similar sales dollars in 2024 compared.
'twenty three on lower volumes.
Based on the current trends.
And take into account the unknowns that exist for the HP situation.
We believe the future quarters for the company will be able to be able to achieve normalized averaged EBITDA run rate of about $20 million per quarter.
And that should be achievable through all of 2000 fiscal 'twenty 2024.
As we begin to utilize the recently added DSA capacity and selling new services and if there is an increase in supply of hp's available for sale.
These estimates may increase.
We continue to expect improvements in our business as we optimize and integrate our DSA and RMS segments and see results from our focus on key initiatives.
We will continue to monitor at BHP situation and adjust our plans accordingly with or without imports from Cambodia.
We understand this is a significant industry issue in the U S and needs to be resolved in order to maximize the industry's ability in the U S to bring important life saving therapies to the market.
Looking to the future.
As we continue to explore how we can better support our customers and their development of novel medicines going forward.
We have embarked on a program to standardize the capture of our data generated.
And discovery safety and clinical studies.
The goal is to structure our data in a way that should in the future enable an AI approach to integrate.
To find correlations between discovery and safety data and clinical outcomes that can innovate and accelerate our translational medicine offering.
Longer term, we are confident in the <unk>.
Service portfolio, we have assembled and continue to optimize.
And our customer service value proposition that is particularly attractive to biopharma sector.
And then the skill and experience of the team we have globally executing on our vision.
With this I would like to turn the call over to Beth.
Financial overview.
Thanks, Bob.
For the nine months ended June 32023 revenues totaled 431 $47 million.
10% increase from the $397 2 million.
During the first nine months of 2022.
RMS revenue for the nine months.
8% to $296 $8 million.
$276 1 million in the same period in 2022.
In our EMEA, we continue to operate in an extremely dynamic pricing environment for larger research models in particular in HP.
DSA revenue for the nine months increased 11% as compared to the same fiscal period last year.
The increase in DSA revenue was primarily driven by additional year to date fiscal 2023 revenue generated from integrated laboratory system that was acquired in January 2022, plus new services related to genetic toxicology.
Janet growth in general toxicology services.
These increases in DSA service revenues were partially offset by decreases in our discovery services, primarily related to the decline in overall biotech funding in the market.
For the 2023 third quarter total revenue decreased 9% to $157 5 million.
$172 $7 million recorded during the prior year period.
DSA revenue for the fiscal third quarter decreased by 5% to $46 8 million when compared to the prior year period.
As previously mentioned the lower revenue in our DSA segment were primarily driven by declines in overall biotech funding in the market.
Timing of general toxicology.
Somewhat offset by increased revenue from genetic toxicology services in connection with our new business.
And our Rockville facility.
Our net revenue for the fiscal third quarter was down 10% to 100.
$10.7 million year over year, mainly due to reduced volume of HP, so somewhat offset by favorable pricing over several product, particularly the next peak.
For the quarter total gross profit improved to $55 2 million or.
35% of total revenues.
$50 9 million or 29, 5% of total revenues.
Last year's third quarter.
Gross profit for our DSA segment in the fiscal third quarter decreased to $17 3 million or 37% of segment revenue from $21 8 million or 44, 3% of segment revenue in last year's third quarter.
We were pleased with the DSA gross profit.
Improvements over the last 12 months.
The decrease in gross profit versus last years Q3 was primarily due to an unusually high gross profit in Q3 of 2022 due to the mix and timing of studies and our safety assessment.
DSA gross profit in 2023 was also impacted by the lower revenue in our discovery.
As our new services start to come online, we expect to generate further demand from both new and current customers alike. Ultimately based on this broader range of services and growth. We believe we will be able to do our.
Our DSA margin from 30% to the mill.
Ed.
30% range in 2024 with long term targets going into the upper 30% range.
The net book to Bill ratio for DSA in the third quarter was one eight times with a slightly positive book to bill for the trailing nine and 12 months.
DSA backlog was 149 1 million.
At June 32023, compared to $143 2 million at June 32022.
Additionally, our conversion rate, which is our ability to convert our backlog to sales has continued to improve over the last three quarters.
RMS segment gross profit in the third quarter of fiscal 2023, with $37 9 million or 34, 2% of total revenues compared to $29 $1 million or 23, 6% of revenues in last year's period, the increase in margin in the current quarter.
It was driven by several factors, including improved pricing for several product lines, partially offset by the absorption of duplicate costs as we implemented our site optimization plan.
General and administrative expenses rose to $26 6 million in the third quarter of fiscal 2023.
One 7 million in last year's second quarter. However, these expenses were down by $2 5 million from Q2 of 2023.
G&A expenses for the third quarter reflected $4 1 million in legal and third party fee, primarily related to Kim podium and HP matters.
Cumberland, Virginia ongoing investigation.
Defense attending Securities litigation and recognition of a charge to fully accrued for settlement.
Ported class action and a related action in California. This summer.
It's subject to court approval.
This compares to the previously reported legal and third party fees in Q2 2023.
$6 $7 million.
Operating income for the quarter was $8 8 million and an inquiry.
$4 8 million of operating income during last year's third quarter.
Reflecting both the $4 $9 million and higher G&A expenses.
And a $4 6 million decrease in other operating expenses, driven primarily by decreased acquisition integration and restructuring expenses.
Interest expense increased to $10 8 million up from $8 4 million in last year's third quarter, reflecting our higher debt balance for borrowing obtain for acquisitions and capital investments and higher interest rates.
Consolidated net income attributable to common shareholders in the third quarter of fiscal 2023 totaled $1 8 million or seven cents per diluted share this compared to consolidated net loss attributable to common shareholders of $3 7 million or 15% loss per day.
Diluted share in the third quarter of 2020 to adjust.
Adjusted EBITDA was $30 5 million or 19, 4% of total revenue as compared to adjusted EBITDA of $37 million or 21, 4% of total revenue in last year's third quarter.
We are pleased with the $35 million of adjusted EBITDA This quarter.
Essentially increased each quarter this year.
Up from adjusted EBITDA of $17 $1 million or 11, 3% of total revenue in the second quarter of fiscal 2023, and a negative $5 5 million of adjusted EBITDA in Q1 of fiscal year 2023.
Net cash provided by operations for the third quarter was $3 7 million compared to cash used by operations of $9 4 million in the same period last year. The increase in cash provided by operations was primarily driven by improved net working capital compared to the same period last year.
Capex in the third quarter was $45 million for two 9% of total revenue and reflected investments in completing our DSA capacity expansions in Rockville, Maryland, and Fort Collins, Colorado enhancements in laboratory technology and improvements for animal welfare.
For the first nine months of fiscal year, 2023 capital expenditures totaled $21 $3 million.
Our balance sheet as of June 32023 included $22 $2 million in cash and cash equivalents as compared to $24 6 million at March 31 2023.
Total debt net of debt issuance costs as of June 32023 was $375 6 million compared.
Compared to $374 $1 million at March 31, 2023. The balance sheet also include assets held for sale of $8 $7 million in liabilities held for sale at $2 $3 million.
Due to the decreasing availability of any piece in the U S. We are recasting our for our full year revenue guidance to at least $570 million in revenue, which is down from $580 million and previous guidance.
We are also updating fiscal 2023, adjusted EBIT guidance to be at least $60 million.
For the year from the previous guidance of $70 million we.
We expect to continue to remain in compliance with our financial covenants for the fiscal year.
We still expect capital expenditures to be approximately 5% of revenue in fiscal 2023.
We anticipate a more modest level of capital investment in 2024 of less than 5%.
The capital expenditures are down from our five year average of 14% as we build capacity new service offerings and implemented our site optimization plan.
We are pleased with our sequential financial performance this fiscal year and the progress that we are seeing from our investments.
Our site optimization implementation and additional capacity investments in our DSA segment, and we remain optimistic as we continue to grow and capture a significant portion of the opportunities in our market.
And with this financial overview, we will turn the call over to our operator for questions.
Yes.
Thank you.
Ladies and gentlemen, we will now begin the question and answer session should you have a question. Please press the star followed by one on your telephone keypad.
<unk> dot comp acknowledging your request questions will be taken in the order received and should you wish to cancel your request. Please press the star followed with up to one moment. Please for your first question.
Thank you and your first question comes from the line of Tim Daley from Wells Fargo. Please go ahead.
Great. Thanks, Thanks for the question here so.
Bob very impressive book to Bill here in DSA at one point Ali.
Roughly 5 million sequential increase in the.
And that orders in the quarter so.
Are there any one off here or any pull forward.
No just how are bookings going in the fourth quarter. So far just trying to kind of help.
Help us figure out our bookings rate on a sequential basis moving forward.
Or bet there are you there to answer Tim.
Question.
I'm, sorry, I'm, sorry, I think I was on mute sorry, Bob.
Yes.
Alright, Tim sorry, Thank you I have been talking here and nobody could hear me I apologize.
So.
To answer your question.
Our bookings for the third quarter were actually very strong one of our strongest ever.
The net bookings so Kim just over one because the cancellations. So we're still seeing a high level of cancellations as we have in previous quarters and I think that will continue it's one of the reasons why we increased the sales force over the last year.
And as we've done that we've seen.
The increase in quotes.
Quoting level for the quarter was probably a record for us.
Our closing and.
We hope to see continue to see those trends one of the areas, where we have been off.
The last six to nine months isn't the discovery services as we've talked about our revenues discovery.
One of the reasons, we decreased guidance is because our discovery revenues are going to be out this year from what we originally projected.
However.
So I also said on the last call in March we added a specific.
Discovery sales team to the market.
Back in the.
First half of this calendar year January February March and we're starting to see really a significant improvement there and I'm starting to see.
Really good trend and the discovery, which maybe is an indication that some of the biotech funding is back and then they are coming back and putting some of their projects back because that's been one of the strength. So far in the first part of this quarter. So I don't have the ability to predict going forward.
How the suit.
With the bookings will be but I do expect cancellations will continue as people were very cautious with your money.
The quoting activity remains fairly strong.
I'm hopeful that we'll continue to close.
A good level.
No.
And <unk>.
So far so far.
Pleased with what we're seeing so far this quarter.
Alright, great and then.
I guess just for Beth.
I think you guys called out assuming that Cambodian China conditions remain.
$20 million quarterly run rate of EBITDA is a good number for 2024, so is that kind of a way to be thinking about at least the baseline for 2024 is $80 million.
EBITDA for the full year and thank you I appreciate it.
Yes, I would be thinking of it in terms of $80 million for the year with an average of $20 million per quarter.
We average if you look at the last two.
Two quarters.
48, which is an average of 24.
And I will say that our.
We look at.
The.
48% reduction of what's coming into the country that there'll be significant reduction we're looking at that.
And pricing and saying, okay, let's make sure as I said.
Set a conservative estimate.
We feel like we can depend on and then if things change.
Biotech funding goes up.
It will recover somebody's server discovery sales, if we're able to see some other additional opportunities for those fees.
Would be great, but at this point.
Let's let's recognize the environment that we're in.
Alright, perfect. Thank you for the time.
Thank you and your next question comes from the line of Matthew <unk> from Craig Hallum Capital Group. Please go ahead.
Good afternoon, thanks for taking the questions and congratulations on navigating what's a pretty challenging environment, maybe first off regarding the NH piece.
I heard what you said as far as Cambodia still pretty locked down it sounds like you are finding some supply in some other.
Geographies or some other countries, but as we think about.
Opportunity there I guess, maybe two questions first.
Were you able to unlock some of your existing inventory or sell some of the existing inventory.
And I guess number two is there an opportunity for you to take.
Taken animals in one or more of your international sites or is that not an option.
What was the last question given that.
Would it be possible yet take to take custody of animals in one of your European locations.
Okay.
First of all we do actually.
Distribute and Hps in Europe .
And we have and that market, we don't we have not.
Taken cambodians into Europe .
Don't expect to have net market truly not changed force. So that has never been part of our capabilities have never been part of our European.
Hi.
Brian .
And we don't anticipate changing that.
We're not going to do anything with the Cambodians for the moment.
Anywhere.
So.
Okay.
That was that part of it.
First part of the question was.
Yes, we have been able to bring in from other countries.
And others.
It kind of depends on what also our customers want but.
You asked about our inventory.
Don't want to give a really don't want to get into a lot of inventory, but yes, we have.
I've said in the past sold program inventory, but.
No we have not sold all of our inventory and we've not released all of our inventory.
Got it Alright, and then maybe a second question.
As you look as you've rolled out some of these new services.
Clearly you're having some success there have you looked at or is there any kind of a metric that you could provide there.
If you look across your 3000 over 3000 customers worldwide. How many are using two services or three services and maybe how is that.
Has that metric changed over the past year. Thank you.
I don't have a good metrics on that Matt I know that we have.
We're bringing our DSA.
<unk> together with <unk>.
And with their safety.
Assessment group.
Finding those.
We're now looking forward, we will we are starting to discuss and figure out how to do a better job of bringing our research models customer base to our discovery base, which evolved into our safety assessment base.
And to do that we'll be making some changes.
And adding some scientific strength to our to our bench.
In the coming year, and looking quite forward to evolving that part of the business that we really can bring the RMS business a lot closer with the discovery business and have the cross sell more than we have in the past, but do that I think we need to make some improvements to the scientific team.
And we are planning to do that.
Those will be announced in the future.
Looking forward to that and.
And I think what we can do now that we've kind of what I would say finished a lot of what were the brick and mortar changes that we needed to make.
And I think there is a lot of opportunity there thought.
A lot of opportunity there we have not touched yet.
Understood. That's helpful. Thank you very much.
Thank you and your next question comes from the line of Steve wildly from Jefferies. Please go ahead.
Hi, good afternoon, Thanks for taking my questions Bob.
I'm wondering if you wouldn't mind breaking out your bookings from some of your newer services I think you've called out in the past.
Ill Pharmaceuticals gene talks I'm wondering how much traction how much.
Those are contributing so far.
Yes, let's see.
Thank you.
I do have a somewhat awareness this and I don't have right in front of me, but we started those services up.
The end of calendar year last year and we.
We've started to see that in the backlog grow and the services start to grow.
It's still.
Phil.
Exceeding $1 million a month in those services for those new facilities.
It's grown.
Fairly rapidly over the last six months and that backlog has grown quite.
Quite a bit but it's maybe put in perspective, maybe 3% to $4 million to $5 million step back call it $4 million of backlog now.
And.
It's really hard to pull apart because many of those services are part of a much larger programs.
And some of those services for things that we were selling before but we are outsourcing.
So okay.
Sometimes it's really hard to say.
That's something we didn't have in our backlog before because of the because what we're outsourcing before.
Okay. Okay. That's good reminder, there.
In that regard sticking on that side of the business, but thinking about.
Your adjusted guidance.
I think youre attributing most of the revenue decline.
In the full year guide to availability of NH piece, you also mentioned in an earlier answer a little bit of discovery.
Yes.
It looks like overall revenue, you're expecting revenue to be sequentially down by $30 million ish dollars.
Should we think about that.
All coming out of RMS.
Some of that.
And I'm thinking again, because your net book to Bill this quarter was pretty decent.
<unk>.
Matt said.
How should we think about canvas.
We're going to see most of that come out of the RMS So and I know, it's not down $30 million I think it's Dan.
We've brought it down $10 million.
$10 million reduction guidance, Amit sequential from the third quarter, sorry, I wasn't clear enough.
Yes, so I think.
So I think it's going to move to where we thought and I think I think that will come more that will come from the RMS side not the.
DSA side.
And that will be primarily an HP related.
So.
For the year.
Our NXP revenues, probably a little higher than I thought we would be.
So our DSA DSA sales that are a little lower than I thought we'd be for the year.
Okay interesting. Okay. So then on the on the RMS side, Ken Ken you or Beth give us a sense of how much of the revenue either for the quarter or.
Year to date.
Is still tied to NH piece, how much how much are in hp's driving RMS now.
Well, it's always been an important part of our revenue.
But.
David put it put a little bit of perspective for.
The volume of <unk> and Hps.
We sold in the third quarter.
This year.
Probably in excess of number of any speed.
Probably.
Leased 40% less than we sold last year.
So when I say that with.
What the imports coming in the U S are getting $40 40.
What is say 49, 49%.
We're seeing that.
As a result, we have much less going out the out the door now on a quarterly basis.
Right on we don't break out so we don't break out I don't think we break out energy revenues from our Ms revenues.
Okay, so but thinking about.
Your commentary, which I appreciate the helpful comments to begin to frame 'twenty four.
Thinking about a.
$110 million number in the third quarter.
And it sounds like your base case expectation is that the volume of.
HP is that will be available to you will continue to shrink.
And so I guess I'm wondering how much of that revenue run rate.
Is.
Subject to the decline in accessibility to NH piece and how much is kind of more stable because it's tied to rodents.
Right.
Here's an interesting thing I think when I just told you the volumes the number the volume of business. Please.
Third quarter was down over last year.
So.
110 included a 40% reduction in volume right.
Alright last year okay.
I think overall, we could be down 40%, 45% next year, So I don't know that.
I think.
Yeah.
I don't know.
We could see a greater fall off next year and the sales of.
<unk> piece that we saw from the <unk> and <unk>.
<unk> business that we saw in the third quarter because that debt.
That is baked in that reduction is significantly baked yet.
I do think that based on when things are coming in.
We could have some variations between quarters of when they.
When they go out so it may not be to every quarter, Steven maybe some quarters are better than others, but I think overall on average the quarter that we saw may be recorded.
With that significantly less volume that we could see.
Okay last question for me is I hope that helps out.
Yeah, Yeah, so so you're kind of saying no more decline.
From the third quarter.
Well and let level third quarter volume.
On average David we could have quarters.
In total.
I think that we see a fairly consistent it doesn't mean every quarter is going to be the same.
Yes.
But on average for the year I think.
Counting on that 40% decline is something that.
40% to 45% decline is something that we.
We're going to have to maybe get used to.
Right. Okay last question from me earlier in the year.
<unk>.
At the <unk> level in the industry level.
There's a lot of conversation about.
Working with the U S Fisher Wildlife service too.
To both get approved kind of have a pathway and get them get approved.
Parentage test.
Just try to SaaS fine kind of reopened the supply chain satisfy the fish and wildlife service about.
The provenance of animals coming from Cambodia, and reopened that supply chain.
Your competitor yesterday, it really didn't come up I'm wondering if you could give us an update on.
Where that stands what progress has been made if any.
And.
And what upcoming court cases, saudis meetings might mean for that.
Dialogue.
Well David Campbell.
And the conclusion that that.
Okay.
We're not we're not big enough and important enough to really make a big difference to what's going to take place with the U S fish and wildlife the Doj to government and those actions we follow it closely.
But theyre going to do what they want to do what they choose to do what they think is best.
And.
I really don't have the ability to predict what they're going to do which I think is why.
We're trying to just be a realistic given the given the landscape we have today.
We're trying to figure out how to play within the landscape we have today if that changes.
Great.
We're ready for it if it doesn't change let's make sure that.
Just to make sure our business model works.
On status quo today.
And I think it's very tough to think for our industry. It's very tough for drug discovery and development in the U S to see that happen, but as far as our company, let's let's take that as the basis and move forward from there instead of every day wake up frustrated that.
It's not that's not changed looks wake up realizing that as today's normal and when it's ready to change we'll be ready for it.
And let's set that expectation and it's really important.
Our management team and I think for our leadership team I want them to wake up every day, knowing they're successful and having them come to work every day thinking theyre not successful because of something we're really waiting for the government to do or not do.
It's not fair to them without fair to us so let's adjust our plans. So they can wake up feeling successful every day and not feel like we are dependent.
That's something we can't control.
Alright understood I appreciate the perspective, thank you.
Thank you.
Your next question comes from the line of Frank that Cannon from Lake Street Capital markets. Please go ahead.
Great. Thanks for taking the questions I wanted to clarify on the renewed EBIT guidance.
I understand the revenue.
Guidance change, but was hoping to get a little bit more color on the EBITDA guidance change figure it would be maybe a little bit less in the same proportion of revenue coming down, but maybe talk to margin expectations. And then is there an expected uptick in operating expense as well to get to that $60 million.
Well there.
For the year.
<unk> I'm pretty pleased with.
Even with the reduction of volume the pricing for that Hps has held up fairly well the RMS sales have held up pretty well.
Really two major things for the for the year that we're offering.
February sales may be down about $10 million from where we'd like them as plans for them to be.
That's a reduction in top line and.
Then, we probably had legal fees in excess of $110 million, where they got to be on.
The discovery sales, probably 80% of that goes to the bottom line.
Those two things make up a pretty big.
I mean that the legal should make up the biggest difference where we're off for this year versus where we hope to be but.
Given all the challenges we had this year and all the changes that are taking place industry in the biotech funding and the NH piece.
We're pretty pleased with this quarter very pleased with where we are today and the ability to get all of these things that we had.
Year ago in December people will talk to you say Howard that world are you going to finish thought four five expansions in eight or nine site closures in <unk>.
Range this and that.
Good news is our organization has done that.
Those things are done so we have a lot less variables.
As far as this quarter.
What we thought is again, just what I told David let's look at where we are realistically.
Within Hps, where we are at the market and let's make sure that we identify something realistic yes, we could.
Yeah, we can leave guidance really high and try to stretch and do something thats not natural for the company.
And achieve a short term.
Quarter to meet it to meet the guidance, but that probably is not the best long term decision for our company. What I tried to give guidance to is what I think is the best long term decision for our company and where best referred to an airport was what is really a reoccurring expectation our last two quarters of pretty good $24 million.
Thank you we can to maintain that.
Yes, our goal is obviously to maintain at least that but look set an expectation that weekend.
Can do.
We feel comfortable with with those lower volumes.
Each piece that we may see in the future.
And the timing when they may come in.
The available for sale.
In some cases, we're expanding the quarantine periods that may take if we do that it would take an extra four weeks of quarantine.
For whatever we're being very careful.
It may choose change when things go out.
And when we ship things.
So now you.
And each piece is growing at 30 to 40000 piece.
Can change.
When 300 Hpe's go out and you just changed your topline and.
And bottom line significantly which is $10 million there.
50% of that go to the bottom line.
Okay.
30%.
<unk>.
There is.
We've got to be very careful of how we set those expectations.
Plus we haven't.
As far as the <unk> business, if you think about it.
We have a very high fixed cost structure and a very high standard for animal welfare.
So even though we have less hp's <unk>, we still have to cover that fixed cost structure.
So.
So those those.
The lower volume that remains we can't take a shortcut on an.
On animal welfare in our investments so.
We're watching those things very closely.
Got it that's helpful. And then now that you have a lot of the site closure broadly speaking site optimization behind you you've got a.
A solid infrastructure to grow off of now maybe speak to your confidence behind your longer term, 18% to 22% EBIT margins and if you're.
And I was thinking about a timeline to when we could reach our profitability profile like that.
Well I think it.
As.
As biotech funding are as we increase our market share.
Have a great leverage I think in our DSA model.
And I think I think there is the outline of those before how we get to those 22%.
With the with increased margins from the DSA business as we grow that.
And.
As the costs continue to come out of our RMS side and those things will continue over the next six to nine months.
What im doing.
<unk>.
Outlining this current guidance is probably taking a lot of pressure.
Growing the DSA sales business.
In the midst of a reduced biotech funding.
I hope we can we grew it.
And Scott.
About 10% last year with 160 to 180, so maybe it's training and $160. So they were low single double digits, maybe we could do that again next year.
When we when we're doing this to two years ago. When biotech funding was high we were growing that business, 25%, 30% a year.
But this environment is a little different but what I'm trying to say is look okay.
It doesn't matter if it takes US 12 months to get their 18 months to get there doesn't need to take six months and let's let's put a realistic expectation.
Yes, I hope, we can get there sooner our team and help them get there sooner and we're looking at.
But sooner and everyone is why we see some pretty good momentum.
So.
If we don't get there next year.
The 22, we did 19% here, obviously, it's possible and we don't even have all the cost.
Savings and we don't have all the margins yet.
Yeah.
So, it's obviously possible for us to get to 'twenty, two but I think what we need to do is make sure we get there in a way that we're building the company.
Strong foundation for the future.
Yeah.
We don't think so.
Mark.
Great makes sense got it thanks for taking the questions I'll stop there.
Thanks.
Thank you and your last question comes from the line of <unk> <unk> from B Riley. Please go ahead.
Thank you for taking our questions Bob on a high level can you provide some comments on the demand although niche piece, how does that compare to last year based on your observation you mentioned the supply of hard from Garmin tracking data.
Couple of follow up questions.
Yes.
Yes, yes.
Our demands.
Staying fairly fairly high and I think it's going to.
Continue to be there.
It is.
Yes.
When this.
The supply.
Chain takes a while to MTS people had inventory people have things in quarantine people have things getting acclimated. So it takes a while for the supply that existed in November to start too.
We've reduced.
Now that we're importing.
What we had before this.
The supply bottlenecks are going to get.
We're going to get a little tougher I believe.
There are also some changes going on and what what type of NXP somebody may want now it may not be.
Cambodia and maybe they are choosing to go to different species. So.
I think there is a shift in and what people are looking for.
We continue to look at that closely but.
I think that the demand is still there if we if we had more I think the demand would be there for more but thats I don't think theres going to be it could be the case.
Got it.
Jason can you. Please clarify the accounting NASA relative to the ISP of biologic assets did you use foreseeing first out lapping last first out to calculate the lithium inventory and Cogs.
Yes.
We use actual.
Actual cost.
So.
Each channel will have its cost of what it cost to bring it to buy it and the imported and so as we sell that the actual cost is.
Against that we do as we as I may or May not have alluded to earlier, we do have overhead has to be covered by those margins.
Such as feeding labor.
Until these sewage insurance transportation.
A lot of those costs are expense theyre not in they're not in our inventory we expense those as we go.
Got it and one last question on the supply all Hp's outside on Cambodia have you will notice an increase our cost of those suppliers and do you have some kind of contract or price locking in place for those supplies.
We do have some price contracts locked in prices.
And yes, we have seen prices increase.
Got it and I expect that Thats, all from launch and you too.
Thank you.
Yes.
Thank you Mr. Alicia there are no further question at this time. Please proceed.
Alright, Thank you everyone for joining today's call.
Great question, So a lot of information.
Our team looks forward to what the future holds for additive.
Positioning the company for strong growth.
Like to thank our investors for being part of this journey with US we understand our industry has faced some challenges and some changes we've made adjustments to address these challenges.
We also believe that <unk>.
Substantial opportunities going forward as all of our efforts to date have significantly enhanced our capabilities in the marketplace.
Moreover, our capital investment program has largely been accomplished already and we expect lower capex spend as a percent of revenue going forward.
Completing the necessary infrastructure upgrades to the business. We now have the advantage of both scale and in house capabilities. We believe that we can continue to effectively increase our sales volume.
Later cross selling to our existing customers, while developing relationships with new customers alike.
We are now well positioned to better control the timing of start in delivery of projects as well as to provide high levels of customer service at all times, we look forward to the next call and seeing.
Many of you at upcoming health care investment conferences.
Thank you and I may add one more happy birthday Robert.
Thank you very much.
Thank you, ladies and gentlemen that does conclude our conference for today. Thank you all for participating you may all disconnect.
Okay.